Comparative Pharmacology
Head-to-head clinical analysis: NARDIL versus PARNATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NARDIL versus PARNATE.
NARDIL vs PARNATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversible, non-selective monoamine oxidase inhibitor (MAOI) that increases synaptic concentrations of monoamines (norepinephrine, serotonin, dopamine) by inhibiting their oxidative deamination.
Irreversible non-selective monoamine oxidase inhibitor (MAOI-A and MAOI-B); increases synaptic concentrations of serotonin, norepinephrine, and dopamine by inhibiting their oxidative deamination.
Initial: 15 mg orally three times daily; increase gradually to 45-60 mg/day in divided doses; maximum 90 mg/day.
10 mg orally twice daily; increase by 10 mg/day at 1-week intervals up to 60 mg/day; usual therapeutic range 30-60 mg/day in divided doses.
None Documented
None Documented
Terminal elimination half-life is approximately 11–13 hours; due to irreversible MAO inhibition, clinical effects persist for 1–2 weeks after discontinuation.
Terminal half-life approximately 2.5 hours; clinically, MAO inhibition persists for 2-3 weeks post discontinuation due to irreversible enzyme binding.
Renal: 70–80% as metabolites and unchanged drug; biliary/fecal: 20–30%.
Renal (90% as metabolites, <1% unchanged); fecal (minor).
Category C
Category C
MAOI Antidepressant
MAOI Antidepressant